Agile Therapeutics, Inc. (AGRX)
Company Description
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States.
Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch.
The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.
The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.
| Country | United States |
| Founded | 1997 |
| IPO Date | May 23, 2014 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Alfred F. Altomari |
Contact Details
Address: 500 College Road East, Suite 310 Princeton, New Jersey 08540-6635 United States | |
| Phone | 609-683-1880 |
| Website | agiletherapeutics.com |
Stock Details
| Ticker Symbol | AGRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001261249 |
| CUSIP Number | 00847L100 |
| ISIN Number | US00847L3087 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Alfred F. Altomari | Chairman and Chief Executive Officer |
| Geoffrey P. Gilmore | Chief Administrative Officer |
| Dr. Paul Korner M.B.A., M.D. | Senior Vice President and Chief Medical Officer |
| Jason Butch | Principal Financial Officer, Vice President and Chief Accounting Officer |
| Matthew Riley | Head of Investor Relations and Corporate Communications |
| Robert G. Conway M.E. | Chief Corporate Planning and Supply Chain Officer |
| Dr. Elizabeth Ijeoma Onyemelukwe Garner M.D., M.P.H. | Consultant |
| Amy Welsh | Chief Commercial Officer |
| Joseph D'Urso | Controller |
| Dr. Kathryn MacFarlane Pharm.D. | Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Dec 11, 2023 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Dec 6, 2023 | 8-K | Current Report |
| Dec 4, 2023 | 8-K | Current Report |
| Nov 9, 2023 | 10-Q | Quarterly Report |
| Nov 9, 2023 | 8-K | Current Report |
| Oct 2, 2023 | 8-K | Current Report |
| Sep 28, 2023 | 8-K | Current Report |
| Aug 22, 2023 | 8-K/A | [Amend] Current report |
| Aug 9, 2023 | 10-Q | Quarterly Report |